Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Drug development and the FDA's Critical Path Initiative.

R L Woosley1, J Cossman

  • 1The Critical Path Institute, Tucson, Arizona, USA. Rwoosley@C-Path.org

Clinical Pharmacology and Therapeutics
|December 23, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A computerized scoring system to improve assessment of heparin-induced thrombocytopenia risk.

Journal of thrombosis and haemostasis : JTH·2018
Same author

Medical decision support systems and therapeutics: The role of autopilots.

Clinical pharmacology and therapeutics·2015
Same author

It is important research, but why is it necessary?

Clinical pharmacology and therapeutics·2013
Same author

Is it possible for FDA regulatory scientists and industry scientists to work together?

Clinical pharmacology and therapeutics·2012
Same author

The Critical Path Institute's approach to precompetitive sharing and advancing regulatory science.

Clinical pharmacology and therapeutics·2010
Same author

The Coalition Against Major Diseases: developing tools for an integrated drug development process for Alzheimer's and Parkinson's diseases.

Clinical pharmacology and therapeutics·2009
Same journal

The Future of Clinical Pharmacology: The Right Medicine at the Right Dose for Each Patient.

Clinical pharmacology and therapeutics·2026
Same journal

Effects of Trimethoprim on Three Previously Proposed Putative Biomarkers for OCT2/MATE-Mediated Renal Drug-Drug Interactions in Healthy Volunteers.

Clinical pharmacology and therapeutics·2026
Same journal

Clinical Characterization of Enzyme and Transporter Precipitants to Evaluate Drug-Drug Interactions for Orforglipron, a Small Molecule Glucagon-Like Peptide-1 Receptor Agonist.

Clinical pharmacology and therapeutics·2026
Same journal

Symposium Report: Stakeholders' Perspectives on Phase 1 Trials in Japanese Prior to Multi-Regional Clinical Trials and Future Pathways.

Clinical pharmacology and therapeutics·2026
Same journal

Resolving CYP2D6 Structural Complexity with Long-Read Sequencing: Implications for Tamoxifen Precision Dosing in Thai Breast Cancer Patients.

Clinical pharmacology and therapeutics·2026
Same journal

Identification of a Functional CYP2C8 Variant Allele that Alters Splicing, Reduces Protein Expression, and Increases Drug Exposure.

Clinical pharmacology and therapeutics·2026
See all related articles

Biomedical research advances promise new therapies, but drug development faces significant translation challenges. Clinical pharmacology offers a strategic approach to enhance the drug development process and overcome these limitations.

Area of Science:

  • Biomedical Research
  • Pharmaceutical Sciences
  • Drug Development

Background:

  • Recent decades have seen substantial advances in biomedical research, increasing expectations for new drug therapies.
  • However, the pharmaceutical industry faces significant limitations in translating this research into successfully marketed therapies.
  • These limitations pose a risk to the effective delivery of new treatments to patients.

Purpose of the Study:

  • To highlight the challenges in translating biomedical research into new therapies.
  • To inform clinical pharmacologists about the signals indicating limitations in drug development.
  • To propose a strategy where clinical pharmacology can improve the drug development process.

Main Methods:

  • Review of current trends in biomedical research and pharmaceutical development.

Related Experiment Videos

  • Analysis of identified limitations in the drug translation pipeline.
  • Discussion of strategic roles for clinical pharmacology in drug development.

    • Main Results:

    • Biomedical research progress has not consistently translated into a proportional increase in marketed therapies.
    • Specific limitations within the drug development process hinder the effective translation of research findings.
    • Clinical pharmacology possesses the potential to address and mitigate these developmental hurdles.

    Conclusions:

    • The pharmaceutical industry's ability to translate biomedical research into new therapies is facing serious limitations.
    • Clinical pharmacologists must be aware of these challenges and their implications.
    • Implementing a strategic role for clinical pharmacology is crucial for improving drug development efficiency and success rates.